INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $624,000 | -29.4% | 42,049 | -5.0% | 0.00% | -25.0% |
| Q2 2021 | $884,000 | +37.9% | 44,259 | +59.5% | 0.00% | +33.3% |
| Q1 2021 | $641,000 | -35.1% | 27,753 | -30.6% | 0.00% | -25.0% |
| Q4 2020 | $988,000 | +51.5% | 40,017 | +154.4% | 0.00% | +33.3% |
| Q3 2020 | $652,000 | -34.3% | 15,730 | -24.1% | 0.00% | -40.0% |
| Q2 2020 | $993,000 | +5.3% | 20,719 | +38.3% | 0.01% | -16.7% |
| Q1 2020 | $943,000 | -49.2% | 14,980 | 0.0% | 0.01% | -33.3% |
| Q4 2019 | $1,856,000 | +278.0% | 14,980 | +102.4% | 0.01% | +200.0% |
| Q3 2019 | $491,000 | +102.9% | 7,400 | +142.9% | 0.00% | +200.0% |
| Q2 2019 | $242,000 | -29.4% | 3,047 | -0.7% | 0.00% | -50.0% |
| Q1 2019 | $343,000 | -49.6% | 3,067 | +6.6% | 0.00% | -71.4% |
| Q2 2014 | $681,000 | – | 2,877 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |